L
Lianbo Yu
Researcher at Ohio State University
Publications - 136
Citations - 7609
Lianbo Yu is an academic researcher from Ohio State University. The author has contributed to research in topics: microRNA & Medicine. The author has an hindex of 33, co-authored 113 publications receiving 5975 citations. Previous affiliations of Lianbo Yu include The Ohio State University Wexner Medical Center.
Papers
More filters
Journal ArticleDOI
Comparative studies of two generations of NanoString nCounter System.
TL;DR: A profiling study to compare performance of two generations of the NanoString nCounter System using a common set of biological samples found that two different generations produced equivalent signals and signal deviations are in the range of random background noises for the medium-high expression levels.
Journal ArticleDOI
Association of Epigenetic Age and p16INK4a With Markers of T-Cell Composition in a Healthy Cohort.
Christin E. Burd,Christin E. Burd,Juan Peng,Bryon Laskowski,Jennifer L. Hollyfield,Suohui Zhang,Paolo Fadda,Lianbo Yu,Rebecca Andridge,Janice K. Kiecolt-Glaser +9 more
TL;DR: It is suggested that PBTL composition has a greater influence on DNAm than p16INK4a and link accelerated epigenetic aging to immunosenescent phenotypes.
Journal ArticleDOI
The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing
Kerry A. Rogers,Dalia El-Gamal,Harrington K. Bonnie,Hing A. Zachary,Goettl M. Virginia,Mantel Rose,Lisa L. Smith,Lianbo Yu,Amy J. Johnson,John C. Byrd,Rosa Lapalombella,Jennifer A. Woyach +11 more
TL;DR: A new model of aggressive B-cell lymphoma to test novel therapeutics that would be more homogeneous than the Eµ-Myc model has differential responses to targeted therapeutics, with a poor response to ibrutinib more similar to aggressive lymphoma than CLL.
Journal ArticleDOI
Stabilin receptors clear LPS and control systemic inflammation.
Fatima Cabral,Mustafa Al-Rahem,John Skaggs,Thushara A. Thomas,Naresh Kumar,Qian Wu,Paolo Fadda,Lianbo Yu,John M. Robinson,Jonghan Kim,Ekta Pandey,Xinghui Sun,Wael N. Jarjour,Murugesan V. S. Rajaram,Edward N. Harris,Latha P. Ganesan +15 more
TL;DR: The authors showed that LPS clearance through LSEC involves endocytosis and lysosomal inactivation via Stabilin-1 and 2 (Stab1 and Stab2) but does not involve TLR4.
Journal ArticleDOI
Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation
Zachary A. Hing,Janek S. Walker,E. Whipp,Lindsey T. Brinton,Matthew Cannon,Pu Zhang,S. Sher,Casey Cempre,Fiona Brown,Porsha Smith,Claudio Agostinelli,Stefano Pileri,Jordan N. Skinner,Katie L. Williams,Hannah Phillips,Jami Shaffer,Larry P Beaver,Alexander Pan,Kyle Shin,C. Thomas Gregory,Gulcin Ozer,Selen A. Yilmaz,Bonnie K. Harrington,Amy Lehman,Lianbo Yu,Vincenzo Coppola,Pearlly S. Yan,Peggy Scherle,Min Wang,Philip Pitis,Chaoyi Xu,Kris Vaddi,Selina Chen-Kiang,Jennifer A. Woyach,James S. Blachly,Lapo Alinari,Yiming Yang,John C. Byrd,Robert A. Baiocchi,Bradley W. Blaser,Rosa Lapalombella +40 more
TL;DR: In this paper , a SAM-competitive protein arginine methyltransferase 5 (PRMT5) inhibitor, PRT382, was proposed to drive oncogenic pathways promoting Richter's Transformation.